# A Study to Assess Sorafenib Alone and in Combination With Low-Dose Interferon Following Unsuccessful Treatment With Sunitinib in Patients With Advanced Renal Cell Cancer.

> **NCT00678288** · PHASE2 · TERMINATED · sponsor: **Bayer** · enrollment: 16 (actual)

## Conditions studied

- Carcinoma, Renal Cell

## Interventions

- **DRUG:** Sorafenib (Nexavar, BAY43-9006)
- **DRUG:** Sorafenib (Nexavar, BAY43-9006) + Interferon

## Key facts

- **NCT ID:** NCT00678288
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-04
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2014-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00678288

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00678288, "A Study to Assess Sorafenib Alone and in Combination With Low-Dose Interferon Following Unsuccessful Treatment With Sunitinib in Patients With Advanced Renal Cell Cancer.". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT00678288. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*